Ac更ces多sib资le v料ers加ion入 知识星球：水木调研纪要 关注公众号：水木纪要 FX Technical Advantage The golden cro$$ strikes again View: The golden cro$$ strikes again 2 5 March 2024 A golden cross (systematic) signal has occurred and favors a supported or stronger DXY FICC Technical Strategy in Q2. Today, March 25, 2024 with a closing price near 104.23, the golden cross signal Global Markets has been confirmed as the 36th signal since 1970 and the 18th since the euro began trading in 1999 (Chart 1). Since 1970, the DXY tended to be hi ...

更多资料加入知识星球：水木调研纪要 关注公众号：水木纪要 FICC Research Economics 30 May 2024 ECB Preview Every journey begins with a single CORE step We expect the ECB to start its easing cycle by cutting rates by European Economics 25bp. The updated inflation forecasts should validate the Mariano Cena decision by showing inflation sustainably at target by mid 2025. +44 (0) 20 7773 0727 mariano.cena@barclays.com The rates guidance should remain unchanged as it provides, for Barclays, UK now, enough flexibility to accommodate diverse e ...

更多资料加入知识星球：水木调研纪要 关注公众号：水木纪要 FICC Research Interest Rates 30 May 2024 European Sovereign Supply Monthly June cash flows decoded CORE We project gross EGB supply totalling c.€105bn in June, with net issuance rising significantly m/m to just over €70bn in a context of notably light redemptions. In Gilts, gross supply should total Max Kitson +44 (0) 20 3134 1456 c.£26bn across six auctions and a single syndication, with the max.kitson@barclays.com net cash call on the market at c.£18.5bn given £7.5bn of Barcla ...

更多资料加入知识星球：水木调研纪要 关注公众号：水木纪要 30 May 2024 | 9:31PM EDT Micron Technology Inc. (MU): Global Semiconductor Conference — Key Takeaways Toshiya Hari +1(646)446-1759 | toshiya.hari@gs.com Goldman Sachs & Co. LLC David Balaban +1(212)357-6369 | david.balaban@gs.com Goldman Sachs & Co. LLC Presenters: Sumit Sadana, Executive Vice President and Chief Business Officer Trevor Janoskie +1(212)357-9851 | trevor.janoskie@gs.com Moderated by: Toshiya Hari, US Semiconductors & Semi Cap Equipment Equity Goldman Sachs & Co. ...

更多资料加入知识星球：水木调研纪要 关注公众号：水木纪要 Viewpoint | 31 May 2024 17:04:27 ET │ 26 pages US Economics Weekly The cycle is turning CITI'S TAKE  Andrew Hollenhorst AC The US economy is clearly slowing down – and in our base case it is headed +1-212-816-0325 for an outright contraction. Consumer spending declined 0.1%MoM in April andrew.hollenhorst@citi.com after Q1 data were revised down to show a more dramatic decline in real goods spending. Core PCE inflation slowed to 0.249%MoM, still elevated, Veronica Clark AC but e ...

更多资料加入知识星球：水木调研纪要 关注公众号：水木纪要 Point | The Global Point Thursday, 30 May 2024 Asia | CEEMEA | Latin America | North America Asia Australia Real Estate - Retail space optimism: declining vacancies, rental gains, and demand-supply balance Over the last 12 months, retail real estate has surprised to the upside with resilient occupancies, improving leasing spread momentum and overall net operating income growth. Higher inflation has supported nominal rental growth for CPI linked leases, whilst lower supply of new ...

30 May 2024 | 9:45PM EDT 17% of total revenue). Organically, the Total System Solution approach continues to be at the core of the company's strategy, while management also remains open to tuck-in deals as evidenced by the recent acquisition of Neuronix AI Labs. Management expects pricing to return to more historical patterns (i.e. flat to slightly down) over the medium- to long-term, but does not expect absolute pricing to revert to pre-pandemic levels given elevated depreciation costs across the industry. ...

Downloaded from Capital IQ by Zoe Shi (zshi@generalatlantic.com) at General Atlantic Service Company, L.P. on Friday May 31 2024 09:16:30 AM, Sessionid:uz33kb2ioepo1sx3rps1zyy3 Ac更ces多sib资le v料ers加ion入知识星球：水木调研纪要 关注公众号：水木纪要 The Flow Show Pain = Gain Scores on the Doors: crypto 51.4%, gold 13.1%, commod 9.1%, stocks 8.9%, oil 8.7%, 3 1 May 2024 US dollar 3.4%, cash 2.2%, HY bonds 1.8%, IG bonds -1.7%, govt bonds -5.6% YTD. Investment Strategy Global Tale of the Tape: political polarization, protectionism, wa ...

Key Points Industry: Biopharma | North America * **Overall Market**: The biopharma industry in North America is experiencing growth, with various therapies showing positive sales trends. * **Oncology**: Oncology drugs, particularly immuno-oncology therapies, are driving growth in the biopharma industry. Key players include Bristol Myers Squibb (Opdivo, Yervoy), Merck (Keytruda), and AstraZeneca (Lynparza). * **BTK Inhibitors**: BTK inhibitors are also a significant growth area, with drugs like Imbruvica, Calquence, and Brukinsa showing strong sales growth. * **Biosimilars**: Biosimilars are gaining market share, with examples including Neulasta, Avastin, and Herceptin biosimilars. Companies * **Bristol Myers Squibb (BMY)**: * Opdivo and Yervoy are leading oncology drugs, with strong sales growth. * Opdivo sales by indication: NSCLC (25%), Melanoma (15%), RCC (10%), HNSCC (5%), Urothelial Carcinoma (5%), and others (5%). * Keytruda sales by indication: NSCLC (24%), Melanoma (8%), H&N (8%), Bladder (8%), MSI-High (11.2%), RCC (8%), TNBC (8%), and others (12.5%). * **Merck (MRK)**: * Keytruda is a leading oncology drug, with strong sales growth. * Keytruda sales by indication: NSCLC (24%), Melanoma (8%), H&N (8%), Bladder (8%), MSI-High (11.2%), RCC (8%), TNBC (8%), and others (12.5%). * **AstraZeneca (AZN)**: * Lynparza is a leading PARP inhibitor, with strong sales growth. * Lynparza received additional approvals for first-line maintenance therapy in ovarian cancer and metastatic castration-resistant prostate cancer. * **AbbVie (ABBV)**: * Imbruvica is a leading BTK inhibitor, with strong sales growth. * Imbruvica sales by indication: MCL (50%), CLL (30%), Waldenstrom's Macroglobulinemia (10%), Marginal Zone Lymphoma (5%), and Chronic GVHD (5%). * **Pfizer (PFE)**: * Bavencio and Imfinzi are leading immuno-oncology drugs, with strong sales growth. * Bavencio sales by indication: Melanoma (50%), NSCLC (25%), SCLC (25%), and others (0%). * Imfinzi sales by indication: NSCLC (50%), SCLC (25%), H&N (25%), and others (0%). * **Johnson & Johnson (JNJ)**: * Erleada and Zytiga are leading androgen receptor inhibitors, with strong sales growth. * Erleada sales by indication: Castration-resistant prostate cancer (metastatic high-risk). * Zytiga sales by indication: Castration-resistant prostate cancer (non-metastatic). * **Amgen (AMGN)**: * Kyprolis is a leading proteasome inhibitor, with strong sales growth. * Kyprolis sales by indication: Multiple Myeloma (100%). Other Important Points * **IQVIA Sales Data**: The report uses IQVIA sales data to analyze market trends and drug sales. * **Normalization**: Sales data is normalized to a 4-week basis to compare with other months. * **Reporting Restrictions**: Some drugs have reporting restrictions due to contractual conditions between suppliers and manufacturers. * **Market Share**: The report also analyzes market share for various drugs and therapies.

更多资料加入知识星球：水木调研纪要 关注公众号：水木纪要 supplier/geography. M Update | --- | --- | --- | |------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...